Atlas Trials

Goldfinch Bio, Inc.

5 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Goldfinch Bio, Inc.

RecordFirmDate
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases (NCT04950114)Goldfinch Bio, Inc.2021-07-27
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes (NCT04880291)Goldfinch Bio, Inc.2021-05-05
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease (NCT04387448)Goldfinch Bio, Inc.2020-07-28
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) (NCT04235621)Goldfinch Bio, Inc.2019-12-20
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects (NCT03970122)Goldfinch Bio, Inc.2019-05-29

Track Goldfinch Bio, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.